Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
759.370.42%
QQQ
716.880.01%
BTC/USD
80725.005.7319%
DIA
515.090.63%
GLD
402.030.92%
TLT
81.180.73%

Kiniksa Pharmaceuticals International PLC (KNSA) Stock Price, Quote, News & History

KNSANASDAQ
Trade with Public
Trade with Public
$78.60
-0.73-0.92%
Last update: Sep 18, 1:04 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Kiniksa Pharmaceuticals (KNSA) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$78.95
Close
-
Volume / Avg.
191.74K / 742.57K
Day Range
$78.03 - $79.61
52 Wk Range
35.20 - 82.94
Market Cap
$6.13B
P/E Ratio
80.05
Dividend Yield
-
Exchange
NASDAQ
RSI
54
Short Interest
9.48%
Days to Cover
8.69

Recent Kiniksa Pharmaceuticals International, PLC News

Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results

US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Pharma, OPKO Health, Itron, up over 20%.
Avi Kapoor

Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.
Avi Kapoor

CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday

U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.
Avi Kapoor

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month

Oversold stocks in health care sector present buying opportunity. RSI compares stock's strength on up/down days & predicts short-term performance. Top oversold stocks: KNSA (28) NNOX (28.2) RNA (28.4).
Avi Kapoor

Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

Avi Kapoor
20%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
184.97M
Investing Cash Flow (TTM)
-239.07M
Financing Cash Flow (TTM)
37.74M
Free Cash Flow (TTM)
182.84M
Capital Expenditure (TTM)
-2.13M
Net Change in Cash (TTM)
-16.36M

Analyst Trends and Forecast

6
Apr
1
Jun
7
Jul
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$5.67B
PE Ratio (TTM)
80.05
PE Ratio (FWD)
61.73
PEG Ratio (TTM)
-
PS Ratio (TTM)
7.72
PB Ratio (TTM)
9.45
Earnings Yield % (TTM)
1.25%
Earnings Yield % (FWD)
1.62%
EV / EBITDA (TTM)
55.53
Price / EBITDA (TTM)
63.64
Price / Free Cash Flow (TTM)
35.52
Book Value / Share
$8.38

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$175.68M
Debt to Equity
0.01
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$78.95
Close
-
Volume / Avg.
191.74K / 742.57K
Day Range
$78.03 - $79.61
52 Wk Range
35.20 - 82.94
Market Cap
$6.13B
P/E Ratio
80.05
Dividend Yield
-
Exchange
NASDAQ
RSI
54
Short Interest
9.48%
Days to Cover
8.69

About

Sector
Health Care
Industry
Biotechnology
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The com...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Kiniksa Pharmaceuticals (KNSA) stock?

A

You can purchase shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Kiniksa Pharmaceuticals (KNSA) competitors?

Q

What is the forecast, or price target, for Kiniksa Pharmaceuticals (KNSA) stock?

A

Kiniksa Pharmaceuticals has a consensus price target of $81.56.

Q

What is the current price for Kiniksa Pharmaceuticals (KNSA)?

A

The stock price for Kiniksa Pharmaceuticals (NASDAQ: KNSA) is $78.6 last updated September 18, 2026 at 1:04 PM EDT.

Q

Does Kiniksa Pharmaceuticals (KNSA) pay a dividend?

A

There are no upcoming dividends for Kiniksa Pharmaceuticals.

Q

When is Kiniksa Pharmaceuticals (NASDAQ:KNSA) reporting earnings?

A

Kiniksa Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Kiniksa Pharmaceuticals (KNSA) going to split?

A

There is no upcoming split for Kiniksa Pharmaceuticals.

Q

What sector and industry does Kiniksa Pharmaceuticals (KNSA) operate in?

A

Kiniksa Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved